Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

China flag China · Delayed Price · Currency is CNY
26.43
+0.28 (1.07%)
Apr 29, 2026, 1:05 PM CST
22.70%
Market Cap 11.92B
Revenue (ttm) 1.42B
Net Income (ttm) 110.05M
Shares Out 455.90M
EPS (ttm) 0.24
PE Ratio 109.25
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,266,900
Average Volume 14,205,403
Open 26.16
Previous Close 26.15
Day's Range 25.91 - 26.44
52-Week Range 20.98 - 32.99
Beta 0.27
RSI 35.05
Earnings Date Apr 25, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 2,014
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600645
Full Company Profile

Financial Performance

In 2025, SHA:600645's revenue was 1.45 billion, a decrease of -8.23% compared to the previous year's 1.59 billion. Earnings were 113.83 million, an increase of 13.43%.

Financial Statements

News

There is no news available yet.